Uncategorized
Macrophage Membrane-Derived Nanoparticles Shows Potential Against Candida Infections
By using tiny particles made from the membranes of human immune cells, scientists from the University of California, San Diego and the University of Missouri have created antifungal nanoparticles that target Candida albicans, a fungus responsible for oral and vaginal yeast infections as well as bloodstream infections. Tests in mice with severe Candida infections show that the macrophage-derived nanoparticles reduced the amount of fungus in major organs, including heart, kidneys, lungs, and spleen. The mice also had improved survival rates.
Full details are published in Cell Biomaterials in a paper titled “Cell membrane-derived nanotherapeutic for combating Candida albicans infections.” In it, the scientists write that “this bioinspired nanodisc not only disrupts fungal membranes directly but also enhances host immune clearance, achieving potent antifungal activity.”
Current treatment options for fungal infections are limited and there are growing concerns about drug resistance. Existing medications typically target specific parts of a fungal cell and can lose effectiveness as fungi evolve resistance. The nanoparticles described in the current paper have a more potent strategy. Besides damaging fungal membranes, they also boost the body’s natural immune defenses to better fight infections.
According to the scientists, each nanodisc measures about 10-20 nanometers, about 1,000 times smaller than a normal macrophage. Their tiny size is an advantage as it allows them to fuse directly with fungal cell membranes and destabilize them, which is harder for full-sized macrophages.
To create the nanodiscs, the scientists isolated the outer membranes of the macrophages and broke up them up into tiny pieces. They then fused them onto disc-shaped nanoparticles made from a biodegradable polymer. Since the nanodiscs are built from macrophage cell membranes, they retain the same receptor proteins that the immune cells use to recognize and attack Candida. This means that the nanodiscs can identify and attach to fungal cells more effectively than those made from other cell types such as red blood cells.
Once attached, the nanodiscs weaken the fungal cell’s protective outer membrane until tiny openings form. As the membrane breaks down, the cell’s contents leak out while external substances seep in ultimately killing the fungus. Because this treatment strategy physically damages the fungal cell rather than targeting a specific molecule, the developers believe that it may be harder for the fungus to evolve resistance.
The nanodiscs also provide other countermeasures. They reverse the suppression of antifungal chemicals produced by macrophages during infection, and prevent Candida from forming biofilms that help to shield fungal cells from drugs and the immune system. Testing also revealed that the treatment was effective when administered both before and after infection suggesting that it could also be used as a preventative.
For their next steps, the scientists will further evaluate the antifungal potency of the nanodiscs against a broader range of pathogenic fungal species.
The post Macrophage Membrane-Derived Nanoparticles Shows Potential Against <i>Candida</i> Infections appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized5 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology8 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read